S&P 500   2,981.46 (+0.52%)
DOW   26,933.32 (+0.54%)
QQQ   192.19 (+0.58%)
FB   186.41 (+1.71%)
MSFT   140.58 (+0.74%)
GOOGL   1,225.81 (+0.66%)
AMZN   1,746.81 (+0.60%)
CGC   19.99 (+5.99%)
NVDA   192.60 (+3.25%)
MU   45.09 (+0.51%)
BABA   173.68 (+1.47%)
GE   8.65 (-0.92%)
TSLA   255.80 (-0.45%)
AMD   30.34 (-0.62%)
T   37.52 (+0.13%)
F   8.88 (+0.57%)
ACB   3.72 (+5.98%)
PRI   121.74 (+0.22%)
NFLX   284.14 (-0.49%)
BAC   29.22 (+0.27%)
GILD   64.76 (+0.39%)
DIS   129.55 (-0.12%)
S&P 500   2,981.46 (+0.52%)
DOW   26,933.32 (+0.54%)
QQQ   192.19 (+0.58%)
FB   186.41 (+1.71%)
MSFT   140.58 (+0.74%)
GOOGL   1,225.81 (+0.66%)
AMZN   1,746.81 (+0.60%)
CGC   19.99 (+5.99%)
NVDA   192.60 (+3.25%)
MU   45.09 (+0.51%)
BABA   173.68 (+1.47%)
GE   8.65 (-0.92%)
TSLA   255.80 (-0.45%)
AMD   30.34 (-0.62%)
T   37.52 (+0.13%)
F   8.88 (+0.57%)
ACB   3.72 (+5.98%)
PRI   121.74 (+0.22%)
NFLX   284.14 (-0.49%)
BAC   29.22 (+0.27%)
GILD   64.76 (+0.39%)
DIS   129.55 (-0.12%)
Log in

BioMarin Pharmaceutical Stock Price, News & Analysis (NASDAQ:BMRN)

$68.03
+0.79 (+1.17 %)
(As of 10/15/2019 09:49 AM ET)
Today's Range
$67.24
Now: $68.03
$68.08
50-Day Range
$64.22
MA: $71.13
$75.95
52-Week Range
$62.88
Now: $68.03
$106.74
Volume18,524 shs
Average Volume1.47 million shs
Market Capitalization$12.21 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.31
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BMRN
CUSIP09061G10
Phone415-506-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.49 billion
Cash Flow$0.22 per share
Book Value$16.67 per share

Profitability

Net Income$-77,210,000.00

Miscellaneous

Employees2,849
Market Cap$12.21 billion
Next Earnings Date10/23/2019 (Confirmed)
OptionableOptionable

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.


BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.16. The biotechnology company earned $388 million during the quarter, compared to analysts' expectations of $415.03 million. BioMarin Pharmaceutical had a negative return on equity of 3.12% and a negative net margin of 7.19%. BioMarin Pharmaceutical's revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.09) earnings per share. View BioMarin Pharmaceutical's Earnings History.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, October 23rd 2019. View Earnings Estimates for BioMarin Pharmaceutical.

How can I listen to BioMarin Pharmaceutical's earnings call?

BioMarin Pharmaceutical will be holding an earnings conference call on Wednesday, October 23rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.68-1.75 billion, compared to the consensus revenue estimate of $1.7 billion.

What price target have analysts set for BMRN?

16 brokers have issued 1-year price targets for BioMarin Pharmaceutical's stock. Their predictions range from $81.00 to $133.00. On average, they expect BioMarin Pharmaceutical's share price to reach $115.33 in the next twelve months. This suggests a possible upside of 69.5% from the stock's current price. View Analyst Price Targets for BioMarin Pharmaceutical.

What is the consensus analysts' recommendation for BioMarin Pharmaceutical?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioMarin Pharmaceutical.

What are Wall Street analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:
  • 1. Cantor Fitzgerald analysts commented, ". We reiterate our OW and $131 PT. We continue to see highly favorable risk/reward ahead of key pipeline updates over the next 12 months. BioMarin reported an in-line quarter, although the overwhelming focus of the call was on valrox (hemophilia A gene therapy). The valrox 3-year update is on track for a top-line by early June (ISTH late-breaker submission due June 7). Not much new color on valrox from the call: management continues to sound confident in durability and potential for accelerated pathway (BMRN’s filing decision by YE19). For investors, we think valrox is more of a show-me story, which is why the update in June is important, although at this point somewhat of an overhang, in our view." (4/26/2019)
  • 2. According to Zacks Investment Research, "BioMarin missed estimates for both earnings and sales in Q4. BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, on the back of strong demand trends. Its newest product, Palynziq’s U.S. launch is progressing well. Its rare disease pipeline is also progressing well. Growing pipeline focus toward gene therapy agents is encouraging However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Moreover, Naglazyme and Vimzin revenues vary on a quarterly basis, primarily owing to infrequent ordering patterns from some countries, mainly Brazil. Meanwhile, BioMarin is facing a generic threat for Kuvan in 2020. The earlier-than-expected entry of generics will be a huge blow for the company." (3/1/2019)

Has BioMarin Pharmaceutical been receiving favorable news coverage?

Press coverage about BMRN stock has been trending very negative recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioMarin Pharmaceutical earned a daily sentiment score of -3.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for BioMarin Pharmaceutical.

Who are some of BioMarin Pharmaceutical's key competitors?

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Array Biopharma (ARRY), Celgene (CELG) and Freeport-McMoRan (FCX).

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:
  • Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)
  • Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)
  • Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61)

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Manning & Napier Group LLC (0.41%), Scout Investments Inc. (0.06%), Gulf International Bank UK Ltd (0.03%), CMH Wealth Management LLC (0.02%), Gradient Investments LLC (0.02%) and Rothschild Investment Corp IL (0.01%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

Which major investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Gulf International Bank UK Ltd, Rothschild Investment Corp IL, Landsberg Bennett & Dubbaneh LLC and Financial Gravity Wealth Inc.. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

Which major investors are buying BioMarin Pharmaceutical stock?

BMRN stock was purchased by a variety of institutional investors in the last quarter, including CMH Wealth Management LLC, Gradient Investments LLC, Manning & Napier Group LLC, Pacer Advisors Inc., North Star Investment Management Corp. and Arden Trust Co. View Insider Buying and Selling for BioMarin Pharmaceutical.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $68.03.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $12.21 billion and generates $1.49 billion in revenue each year. The biotechnology company earns $-77,210,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. BioMarin Pharmaceutical employs 2,849 workers across the globe.View Additional Information About BioMarin Pharmaceutical.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is http://www.bmrn.com/.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]


MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,243 (Vote Outperform)
Underperform Votes:  694 (Vote Underperform)
Total Votes:  1,937
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Featured Article: Moving Average (MA)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel